

A GWAS follow-up study reveals the association of the *IL12RB2* gene with systemic sclerosis in Caucasian populations

Lara Bossini-Castillo^{1,*}, Jose-Ezequiel Martin¹, Jasper Broen², Olga Gorlova³, Carmen P. Simeón⁴, Lorenzo Beretta⁵, Madelon C. Vonk², Jose Luis Callejas⁶, Ivan Castellví⁷, Patricia Carreira⁸, Francisco José García-Hernández⁹, Mónica Fernández Castro¹⁰, the Spanish Scleroderma Group[†], Marieke J.H. Coenen¹¹, Gabriela Riemekasten¹², Torsten Witte¹³, Nicolas Hunzelmann¹⁴, Alexander Kreuter¹⁵, Jörg H.W. Distler¹⁶, Bobby P. Koeleman¹⁷, Alexandre E. Voskuyl¹⁸, Annemie J. Schuerwegh¹⁹, Øyvind Palm²⁰, Roger Hesselstrand²¹, Annika Nordin²², Paolo Airó²³, Claudio Lunardi²⁴, Raffaella Scorza⁵, Paul Shiels²⁵, Jacob M. van Laar²⁶, Ariane Herrick²⁷, Jane Worthington²⁷, Christopher Denton²⁸, Filemon K. Tan²⁹, Frank C. Arnett²⁹, Sandeep K. Agarwal²⁹, Shervin Assassi²⁹, Carmen Fonseca²⁸, Maureen D. Mayes²⁹, Timothy R.D.J. Radstake² and Javier Martin¹

¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada 18100, Spain ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen 6525, The Netherlands ³Department of Epidemiology, M.D. Anderson Cancer Center, Houston, TX 77030, USA ⁴Servicio de Medicina Interna, Hospital Valle de Hebron, Barcelona 08035, Spain ⁵IRCCS Fondazione Policlinico-Mangiagalli-Regina Elena & University of Milan, Allergy, Clinical Immunology and Rheumatology, Milan 20122, Italy ⁶Unidad de Enfermedades Sistémicas Autoinmunes, Servicio de Medicina Interna, Hospital Clínico Universitario San Cecilio, Granada 18012, Spain ⁷Servicio de Reumatología, Hospital Sant Pau, Barcelona 08025, Spain ⁸Servicio de Reumatología, Hospital 12 de Octubre, Madrid 28041, Spain ⁹Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla 41013, Spain ¹⁰Servicio de Reumatología, Hospital Universitario Puerta del Hierro Majadahonda, Madrid 28222, Spain ¹¹Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen 6525, The Netherlands ¹²Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin 12203, Germany ¹³Hannover Medical School, Hannover 30625, Germany ¹⁴Department of Dermatology, University of Cologne, Cologne 50923, Germany ¹⁵Ruhr University of Bochum, Bochum 44801, Germany ¹⁶Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen 91054, Germany ¹⁷Section Complex Genetics, Department of Medical Genetics, University Medical Center Utrecht, Utrecht 3508AB, The Netherlands ¹⁸Department of Rheumatology, VU University Medical Center, Amsterdam 1081, The Netherlands ¹⁹Department of Rheumatology, Leiden University Medical Center, Leiden 2333, The Netherlands ²⁰Department of Rheumatology, Rikshospitalet, Oslo University Hospital, Oslo 0027, Norway ²¹Department of Rheumatology, Lund University, Lund 222 41, Sweden ²²Karolinska Institute, Stockholm 171 77, Sweden ²³Servizio di Reumatologia ed Immunologia Clinica Spedali Civili, Brescia 25018, Italy ²⁴Department of Medicine, Università degli Studi di Verona, Verona 37129, Italy ²⁵University of Glasgow, Glasgow G12 8QQ, UK ²⁶Institute of Cellular Medicine, Newcastle University, Newcastle NE2 4HH, UK ²⁷Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PT, UK ²⁸Centre for Rheumatology, Royal Free and University College Medical School, London NW3 2QG, UK ²⁹The University of Texas Health Science Center–Houston, Houston, TX 77030, USA

Received June 1, 2011; Revised October 28, 2011; Accepted November 7, 2011

*To whom correspondence should be addressed at: Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-Ctable SIC), Consejo Superior de Investigaciones Científicas, Parque Tecnológico Ciencias de la Salud. Avenida del Conocimiento s/n 18100-Armiilla, Granada, Spain. Tel: +34 958181621; Fax: +34 958181632; Email: larabc@ipb.csic.es

[†]The authors are listed in Appendix.

A single-nucleotide polymorphism (SNP) at the *IL12RB2* locus showed a suggestive association signal in a previously published genome-wide association study (GWAS) in systemic sclerosis (SSc). Aiming to reveal the possible implication of the *IL12RB2* gene in SSc, we conducted a follow-up study of this *locus* in different Caucasian cohorts. We analyzed 10 GWAS-genotyped SNPs in the *IL12RB2* region (2309 SSc patients and 5161 controls). We then selected three SNPs (rs3790567, rs3790566 and rs924080) based on their significance level in the GWAS, for follow-up in an independent European cohort comprising 3344 SSc and 3848 controls. The most-associated SNP (rs3790567) was further tested in an independent cohort comprising 597 SSc patients and 1139 controls from the USA. After conditional logistic regression analysis of the GWAS data, we selected rs3790567 [$P_{MH} = 1.92 \times 10^{-5}$ odds ratio (OR) = 1.19] as the genetic variant with the firmest independent association observed in the analyzed GWAS peak of association. After the first follow-up phase, only the association of rs3790567 was consistent ($P_{MH} = 4.84 \times 10^{-3}$ OR = 1.12). The second follow-up phase confirmed this finding ($P_{\chi^2} = 2.82 \times 10^{-4}$ OR = 1.34). After performing overall pooled-analysis of all the cohorts included in the present study, the association found for the rs3790567 SNP in the *IL12RB2* gene region reached GWAS-level significant association ($P_{MH} = 2.82 \times 10^{-9}$ OR = 1.17). Our data clearly support the *IL12RB2* genetic association with SSc, and suggest a relevant role of the interleukin 12 signaling pathway in SSc pathogenesis.

INTRODUCTION

Systemic sclerosis or scleroderma (SSc) is a rare complex connective tissue disorder characterized by extensive fibrosis of multiple organs produced by vascular damage and autoimmune dysfunction (1,2). Patients are commonly classified into two major subgroups: the limited cutaneous SSc (lcSSc) and the diffuse cutaneous (dcSSc) form of the disease (3). Positive autoantibody titers are a main feature of this disabling condition, especially anticentromere autoantibodies (ACA) and antitopoisomerase autoantibodies (ATA) (1,2). To date, a number of genes have been implicated in an increased susceptibility to SSc, confirming the genetic component of this complex disease (4,5). Some of these genes are shared with other related autoimmune diseases, supporting the idea of common pathogenic pathways underlying autoimmune imbalance (6,7).

Recently, our group published the first genome-wide association study (GWAS) conducted in Caucasian SSc patients (5). GWASs are often followed by follow-up studies focused on the regions where association peaks are observed, not only in the associations which reached the GWAS significance level, but also those which are below the GWAS level but might result in true association with the disease. In this line, a single-nucleotide polymorphism (SNP) at the *IL12RB2* locus showed a suggestive association signal in the previously mentioned GWAS [$P_{MH} = 1.92 \times 10^{-5}$ odds ratio (OR) = 1.19 (1.10–1.29)] (5).

Noteworthy, interleukin 12 (IL-12) binding to its receptor powerfully induces IFN γ production and promotes T helper differentiation in Th1 cells (8). In addition, several experimental and clinical studies have implicated IL-12 and IFN γ in the development of autoimmune inflammation (8,9). The IL-12 receptor (IL-12R) comprises two subunits, IL-12R β 1 subunit (IL-12R β 1) and IL-12R β 2 subunit (IL-12R β 2), which are both homologous to gp130 (a shared component of the receptors for several type I cytokines) (10).

IL12RB2 encodes IL-12R β 2, which constitutes the transducing component of the receptor heterodimer and recruits different tyrosine kinases, signal transducers and activators of transcription (11–13). Interestingly, animal models lacking

IL12R β 2 signaling develop autoimmune events (14). Moreover, polymorphisms in the *IL12RB2* gene region and upstream this locus have been related to several human autoimmune disorders, such as psoriasis (PS) (15), primary biliary cirrhosis (PBC) (16), Behçet disease (17,18) and giant cell arteritis (GCA) (19).

Hence, with the aim of investigating the possible role of the *IL12RB2* gene in SSc, we conducted a GWAS follow-up study in different European and US Caucasian cohorts.

RESULTS

IL12RB2 region analysis in the GWAS set

Ten SNPs in the *IL12RB2* region were included in the initial GWAS analysis set, six of them were found to be significantly associated with SSc, but only four remained significant after GC correction (Table 1). However, conditioned logistic regression revealed that among the initially observed associations, only the rs3790567 association was independent from the others (Table 1). HapMap linkage disequilibrium patterns defined rs3790566 (not included in the GWAS phase) as the unique tag-SNP for rs3790567. Hence, both the most-associated SNP (rs3790567) and this tag-SNP (rs3790566) were selected for replication.

Despite the loss of the observed association after correction for multiple testing (Table 1), we also included rs924080 in the first follow-up phase. This genetic variant was located in the intergenic region between *IL12RB2* and *IL23R*, and it was the last GWAS SNP contained in the *IL23R* haplotype block (Fig. 1). In addition, this polymorphism mapped in a recombination hotspot identified in the HapMap Project (Phase II, Caucasian and Asian populations; <http://www.hapmap.org>) and previous reports (17).

European follow-up phase

Table 2 shows the pooled analysis of seven independent white European cohorts of the three SNPs analyzed in the first follow-up phase. No evidence of association was observed

Table 1. Pooled logistic regression of *IL12RB2* genetic variants in the GWAS cohort (2309 SSc patients and 5161 controls)

SNP	Chr: 1 position (bp)	Minor allele	P_{\log}	OR	P_{GC}	P -value: add to rs3790567	OR and rs3790567	P -value rs3790567 add to SNP	OR rs3790567 and to SNP	r^2 with rs3790567
rs924080	67,532,728	G	2.93×10^{-2}	1.08	3.91×10^{-2}	0.12	1.06	2.16×10^{-5}	1.19	0.02
rs12131065	67,541,594	A	0.16	0.94	0.18	0.20	0.95	7.72×10^{-6}	1.19	0.001
rs3790558	67,549,609	C	0.31	1.04	0.34	0.19	0.95	4.74×10^{-6}	1.23	0.23
rs10489627	67,552,264	G	4.88×10^{-2}	1.08	0.06	0.83	0.99	4.98×10^{-5}	1.20	0.23
rs2066445	67,554,563	A	0.09	0.93	0.11	0.11	0.93	7.62×10^{-6}	1.20	0.0005
rs3790567	67,594,965	A	6.36×10^{-6}	1.20	1.92×10^{-5}	NA	NA	NA	NA	NA
rs3828069	67,612,161	G	4.24×10^{-2}	0.91	0.05	0.44	0.96	4.28×10^{-5}	1.19	0.08
rs4297265	67,624,923	G	1.71×10^{-2}	1.09	2.41×10^{-2}	0.39	0.96	9.86×10^{-5}	1.23	0.44
rs2270614	67,628,609	A	1.66×10^{-2}	1.09	2.34×10^{-2}	0.41	0.96	1.04×10^{-4}	1.23	0.44
rs7555183	67,633,215	A	0.24	1.05	0.27	0.92	1.00	1.31×10^{-5}	1.20	0.08

Chr, chromosome; P_{\log} , logistic regression P -value; OR, odds ratio; P_{GC} , GC corrected P -value. Last columns, single locus test P -value when SNP added to rs3790567, single locus test OR when SNP added to rs3790567, single locus test P -value when rs3790567 added to SNP in logistic regression analyses, single locus test OR when rs3790567 added to SNP in logistic regression analyses and pairwise r^2 of SNP with rs3790567. NA, not applicable.

for rs924080. Despite an initial association of rs3790566 and rs3790567, after performing Bonferroni multiple test correction only the association of rs3790567 remained significant (Table 2). The pooled analysis of this genetic variant in the GWAS cohort and the independent follow-up set reached a notable statistically significant association [$P_{MH} = 5.19 \times 10^{-7}$ OR = 1.16 (1.09–1.22), Table 3].

The subgroup and autoantibody titer stratified pooled analyses comprising the GWAS and the European follow-up cohorts showed firm statistically significant risk association signals in all the subgroups of the disease considered (Supplementary Material, Tables S1–S2).

US follow-up phase

In order to confirm the rs3790567 signal, an independent US cohort was included (597 SSc and 1139 controls). Case–control frequency analysis revealed a strong association [$P_{\chi^2} = 2.82 \times 10^{-4}$ OR = 1.34 (1.14–1.57), Table 3]. After stratification, only lcSSc subgroup reached statistical significance, probably due to a lack of power since the other subgroups are relatively smaller (Supplementary Material, Tables S1–S2).

The overall pooled analysis of rs3790567 comprising the GWAS set and both the European and the US follow-up sets reached GWAS-level statistically significant association in the whole set of SSc patients [$P_{MH} = 2.82 \times 10^{-9}$ OR = 1.17 (1.11–1.24)] and remained significant after stratification in all the subgroups (Table 3 and Supplementary Material, Tables S1–S2). Hence, we suggest that the association found in rs3790567 most likely belonged to the whole SSc set of patients rather than any of its subgroups. The rs3790567 individual population allele distributions and association tests are shown in Supplementary Material, Tables S3–S5.

IL23R locus dependence analysis

Aiming to further confirm the independence of the reported *IL12RB2* signal from the *IL23R* locus, we analyzed the association of the SNPs in the *IL23R* region which were included in the GWAS initial phase and their effect on the *IL12RB2*

rs3790567 association. The *IL23R* region comprised 27 SNPs and only 4 of them showed some marginal association with SSc, considering uncorrected P -values (Supplementary Material, Table S7). Nevertheless, the association observed in rs3790567 was found independent of these weak signals (Supplementary Material, Table S7).

DISCUSSION

Our data clearly support an association of *IL12RB2* rs3790567 with SSc. The risk effect of the *IL12RB2* rs3790567 minor allele is consistent in all the analyzed cohorts with the exception of the Italian population. In contrast to other cohorts, the minor allele rs3790567*A is over-represented in controls compared with SSc patients in the Italian sample set. The Italian control group showed the highest minor allele frequency among all the included populations, and the linkage disequilibrium between rs3790567 and rs3790566 in the Italian cohort was considerably lower ($r^2 = 0.70$) than in the other European populations ($r^2 > 0.90$). In addition, this over-representation of the rs3790567*A minor allele is also observed in the TSI (Tuscan in Italy) population in the HapMap Project (Phase III) ($MAF_{TSI} = 0.30$) when compared with the CEU population ($MAF_{CEU} = 0.26$). However, the linkage disequilibrium observed between rs3790567 and rs3790566 in the Hapmap TSI population compared with the CEU population decreased very slightly ($r^2_{TSI} = 0.97$, $r^2_{CEU} = 1$). Hence, it is likely that the observed discrepancies in the Italian set were due to ethnic differences in linkage disequilibrium patterns. Supporting this notion, BD test revealed significant heterogeneity in the lcSSc overall pooled analysis caused by the Italian patients (P_{BD} with the Italian population = 0.04; P_{BD} without the Italian population = 0.45). Although cases and controls were geographically matched, the potential effect of population substructure in the replication cohorts could not be controlled by deriving principal components on a population-specific basis, as it was performed for the GWAS cohorts, due to the lack of high-throughput genotype information for these individuals. Considering the reported heterogeneous genetic background for Italian populations (20), the influence of this factor on the deviation observed in our Italian subset cannot be ignored.




Figure 1. GWAS phase of the *IL12RB2* region. Regional association plot, recombination rate, linkage disequilibrium pattern and pairwise r^2 of the SNPs with rs3790567.

Table 2. Genotype and allele distribution of *IL12RB2* genetic variants in the European SSc patients and controls follow-up study (3344 SSc/3848 controls)

SNP	1/2	CTRL			SSc			MAF	P_{MH}	OR	95% CI	P_{Bonf}	P_{BD}	
		1/1 (n)	1/2 (n)	2/2 (n)	MAF	1/1 (n)	1/2 (n)							2/2 (n)
rs924080	C/T	0.22 (827)	0.48 (1807)	0.29 (1094)	0.46	0.22 (687)	0.49 (1545)	0.30 (934)	0.46	0.96	1.00	0.93–1.07	1	NS
rs3790566	T/C	0.08 (280)	0.37 (1334)	0.55 (1978)	0.26	0.09 (273)	0.39 (1196)	0.52 (1617)	0.28	3.35×10^{-2}	1.09	1.01–1.18	0.10	NS
rs3790567	A/G	0.08 (241)	0.37 (1169)	0.56 (1773)	0.26	0.09 (282)	0.38 (1187)	0.52 (1616)	0.28	4.84×10^{-3}	1.12	1.04–1.22	0.01	NS

SSc, systemic sclerosis patients; CTRL, healthy controls; 1/2, minor allele/major allele; MAF, minor allele frequency; P_{MH} , allelic Mantel–Haenszel fixed effects model P -value; OR, odds ratio; 95% CI, 95% confidence interval; P_{BD} , Breslow–Day test P -value; NS, not statistically significant.

As stated above, different *IL12RB2* genetics variants have been associated with multiple autoimmune disorders (15–19). However, the fact that the same *IL12RB2* variant, rs3790567, has been associated with increased susceptibility to both PBC and GCA (16,19), together with the lack of association in our data of a nearby highly linked variant (rs3790566), suggest that rs3790567 intronic SNP may be tagging a functional variant or even has a yet unknown functional implication itself.

The *IL12RB2* gene maps close to the IL-23R coding gene (*IL23R*), which are located <50 kb from each other. IL-23R binds IL-12R β 1 chain constituting the heterodimeric receptor for IL-23 (21). Although *IL23R* polymorphisms have been associated with different autoimmune diseases (22–28), its

implication in SSc is not clear (29–31). In this report, conditional regression analyses showed that the association of *IL12RB2* rs3790567 with SSc is independent from all the studied *IL23R* genetic polymorphisms, even from *IL23R* rs11209026 (Arg281Gln) missense variant. Hence, we suggest that the reported association of the *IL12RB2* gene with SSc susceptibility does not rely on the *IL23R* locus. Nevertheless, further studies will be necessary to investigate the possible effect of *IL12RB2* genetic variants on *IL23R* gene expression.

IL-12 levels are increased in the serum of SSc patients as well as in the alveolar lavage fluid (BAL-f) from patients with SSc-associated interstitial lung disease (ILD) (32,33). Although IL-12 classical implication in immune imbalance

Table 3. Genotype and allele distribution of *IL12RB2* rs3790567 genetic variant in SSc patients and controls in a three-step association study

Population (CTRL/SSc)	CTRL				SSc				P_{MH}	OR	95% CI	P_{BD}
	AA (n)	AG (n)	GG (n)	MAF	AA (n)	AG (n)	GG (n)	MAF				
GWAS cohort (5161/2309)	0.06 (332)	0.37 (1911)	0.57 (2918)	0.25	0.08 (196)	0.40 (919)	0.52 (1194)	0.28	1.92×10^{-5}	1.19	1.10–1.29	NS
European follow-up (3183/3085)	0.08 (241)	0.37 (1169)	0.56 (1773)	0.26	0.09 (282)	0.38 (1187)	0.52 (1161)	0.28	4.84×10^{-3}	1.12	1.04–1.22	NS
GWAS + European follow-up (8344/5394)	0.07 (573)	0.37 (3080)	0.56 (4691)	0.25	0.09 (478)	0.39 (2106)	0.52 (2810)	0.28	5.19×10^{-7}	1.16	1.09–1.22	NS
US follow-up (1139/597)	0.05 (60)	0.37 (417)	0.58 (662)	0.24	0.10 (59)	0.39 (231)	0.51 (307)	0.29	2.82×10^{-4}	1.34	1.14–1.57	NA
GWAS + European + US follow-up (9483/5991)	0.07 (633)	0.37 (3497)	0.56 (5353)	0.25	0.09 (537)	0.39 (2337)	0.52 (3117)	0.28	2.82×10^{-9}	1.17	1.11–1.24	NS

Controls are used as reference for all comparisons. CTRL, healthy controls; SSc, systemic sclerosis; MAF, minor allele (A) frequency; P_{MH} , allelic Mantel–Haenszel fixed effects model P -value; ^aallelic Chi-square uncorrected P -value; OR, odds ratio; 95% CI, 95% confidence interval; P_{BD} , Breslow–Day test P -value; NS, not statistically significant; NA, not applicable.

has been mainly related to a pro-inflammatory cell-mediated immunity and Th1 response (9) and increased levels of IL-12 correlate with renal vascular damage (32), the role of IL-12 in SSc pathogenesis should be considered cautiously. Indeed, SSc patients and especially those with ILD have a Th2-polarized response (34). Additionally, it has been suggested that IL-12 drives a drift from a Th2 to Th1 response which improves skin score in SSc patients (35). Moreover, IL-12 is known to have anti-fibrotic effects in fibroblasts (36), and the administration of IL-12 coding plasmid to the tight skin SSc mouse model prevents collagen accumulation in the skin (37). On the other hand, the implication IL-12Rβ2 in autoimmune events seems to be complex as well. For instance, IL12rb2 knock-out mice do not display IL-12-mediated NK cytotoxicity (38) and the IL-12/IL-12Rβ2 axis is known to be critical for the generation of Th1 autoreactive cells (39), but, despite this, these mice develop spontaneous autoimmune pathology (immune-complex glomerulonephritis) and B-cell tumors by a strong IL-6 up-regulation (14,40). In addition, IL-12R signals predominantly through the STAT pathway, especially STAT4 (37,40). In this regard, it should be noted that polymorphisms in the *STAT4* gene are well-established risk factors for SSc (4). Hence, it is likely that genetically predisposed individuals may present subtle differences in IL-12 signaling pathway regulation that could influence the prognosis of SSc.

To date, only a few SSc-related loci have reached a GWAS-level significance (i.e. P -value $< 5.00 \times 10^{-8}$), both in the previously mentioned GWAS and recent studies: the HLA region, *STAT4*, *TNPO3-IRF5*, *CD247*, *PSORS1C1*, *TNIP1* and *IRF8* (5,41,42). Hence, we consider that the reported GWAS-level significant association may firmly contribute to the genetic knowledge of the disease.

In conclusion, we report for the first time the association of an *IL12RB2* genetic variant with SSc. Our data together with previous reports identify *IL12RB2* as a common genetic risk factor for autoimmunity.

MATERIALS AND METHODS

Subjects

The GWAS cohort was comprised of 2309 SSc patients and 5161 controls of Caucasian ancestry from Spain, Germany,

The Netherlands and USA from a previously published study (5). The first follow-up phase consisted of 3085 SSc patients and 3183 controls from seven European Caucasian cohorts (Spain, Germany, The Netherlands, Italy, Sweden, UK and Norway). The second follow-up step comprised 1736 additional USA Caucasian individuals (597 SSc and 1139 controls). All the patients fulfilled the 1980 American College of Rheumatology (ACR) classification criteria for SSc (43) or the criteria proposed for early-SSc (44). In addition, patients were classified as having lcSSc or dcSSc as described in LeRoy *et al.* (3).

The following clinical data were collected for the ascertainment of the clinical phenotype of SSc patients: age, gender and presence of SSc-specific autoantibodies (Ab) ATA and ACA (Supplementary Material, Table S6). The control population consisted of unrelated healthy individuals recruited in the same geographical regions as SSc patients and matched by age, sex and ethnicity with the SSc patients groups.

The study was approved by local ethical committees from all the participating centers. Both patients and controls were included in the study after written informed consent. DNA from patients and controls were obtained using standard methods.

SNP selection

In the screening GWAS phase, we included a 116 kb region spanning the *IL12RB2* region and ~13 kb upstream and downstream from this locus, from base pair 67 530 000 to 67 646 000 in chromosome 1, in the GWAS cohorts. After QC filtering as described in Radstake *et al.* (5), genotyping data for 10 SNPs over this region on chromosome 1 were available. The same procedure was applied for the analysis of the *IL23R* region, which comprised 163 kb and 27 SNPs.

TaqMan SNP genotyping of the follow-up cohorts was performed in a 7900HT Real-Time Polymerase Chain Reaction (PCR) System from Applied Biosystems following the manufacturer's suggestions (Foster City, CA, USA).

Statistical analysis

Significance was calculated using 2×2 contingency tables and Fisher's exact test or χ^2 when necessary, to obtain P -values, OR and 95% confidence intervals using PLINK

(v1.07) software (<http://pngu.mgh.harvard.edu/purcell/plink/>). *P*-values below 0.05 were considered statistically significant. Bonferroni correction and GC as described in Radstake *et al.* (5) were applied. The Hardy–Weinberg equilibrium (HWE) was tested for all the SNPs comparing the observed genotype distribution in controls with the expected genotype distribution under HWE by means of Fisher's exact test or χ^2 when necessary as described in Radstake *et al.* (5). The logistic regression and conditioned logistic regression analyses (considering the different cohorts as covariables) were performed using PLINK software. Linkage disequilibrium patterns across the region in the HapMap Project Phase I and II (CEU population) defined the haplotype-tagging SNPs using Haploview (v.4.2) software (<http://www.broadinstitute.org/haploview/haploview>). The SNPs included in the GWAS phase were forced-included in the list of SNPs. Over this region on chromosome 1, the recombination rate was estimated from HapMap public database using LocusZoom (v.1.1) software (<http://csg.sph.umich.edu/locuszoom/>) (45). SNP & Variation Suite Version 7.5.1 (Golden Helix Inc.) and LocusZoom software were used for the composition of Figure 1. Cochran–Mantel–Haenszel meta-analysis was performed to control for the differences among populations as implemented in PLINK software. In addition, the Breslow–Day test (BD test) was performed as implemented in PLINK in each meta-analysis to assess the homogeneity of the association among populations. The power of the whole set of SSc patients and controls reached 100%. Power was calculated using the software Power Calculator for Genetic Studies 2006 (46) and assuming an additive model (*P*-value = 0.01 OR = 1.20). The genotyping success call rate in the GWAS cohort was of 99.8%, while in the replication set was over 95%.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at *HMG* online.

ACKNOWLEDGEMENTS

We thank Sofia Vargas, Sonia García and Gema Robledo for their excellent technical assistance and all the patients and control donors for their essential collaboration. We thank Banco Nacional de ADN (University of Salamanca, Spain) and the Norwegian Bone Marrow Donor Registry who supplied part of the control DNA samples. We are also thankful to EUSTAR (The EULAR Scleroderma Trials and Research group) and the German Network of Systemic Sclerosis for the facilitation of this project.

Conflict of Interest statement. None declared.

FUNDING

This work was supported by the following grants: J.M. was funded by GEN-FER from the Spanish Society of Rheumatology, SAF2009-11110 from the Spanish Ministry of Science, CTS-4977 from Junta de Andalucía, Spain, in part by Redes Temáticas de Investigación Cooperativa Sanitaria Program,

RD08/0075 (RIER) from Instituto de Salud Carlos III (ISCIII), Spain and by Fondo Europeo de Desarrollo Regional (FEDER). T.R.D.J.R. was funded by the VIDI laureate from the Dutch Association of Research (NWO) and Dutch Arthritis Foundation (National Reumafonds). J.M. and T.R.D.J.R. were sponsored by the Orphan Disease Program grant from the European League Against Rheumatism (EULAR). B.P.C.K. is supported by the Dutch Diabetes Research Foundation (grant 2008.40.001) and the Dutch Arthritis Foundation (Reumafonds, grant NR 09-1-408). T.W. was granted by DFG WI 1031/6.1 and DFG KFO 250 TP03. N.O. was funded by PI-0590-2010, Consejería de Salud, Junta de Andalucía, Spain. The USA studies were supported by NIH/NIAMS Scleroderma Registry and DNA Repository (N01-AR-0-2251), NIH/NIAMS-RO1-AR055258 and NIH/NIAMS Center of Research Translation in Scleroderma (1P50AR054144) and the Department of Defense Congressionally Directed Medical Research Programs (W81XWH-07-01-0111).

APPENDIX

Spanish Scleroderma Group: Norberto Ortego-Centeno and Raquel Ríos, Unidad de Enfermedades Sistémicas Autoinmunes, Servicio de Medicina Interna, Hospital Clínico Universitario San Cecilio, Granada; Nuria Navarrete, Servicio de Medicina Interna, Hospital Virgen de las Nieves, Granada; Rosa García Portales, Servicio de Reumatología, Hospital Virgen de la Victoria, Málaga; María Teresa Camps, Servicio de Medicina Interna, Hospital Carlos Haya, Málaga; Antonio Fernández-Nebro, Servicio de Reumatología, Hospital Carlos Haya, Málaga; María F. González-Escribano, Servicio de Inmunología, Hospital Virgen del Rocío, Sevilla; Julio Sánchez-Román and M^a Jesús Castillo, Servicio de Medicina Interna, Hospital Virgen del Rocío, Sevilla; M^a Ángeles Aguirre and Inmaculada Gómez-Gracia, Servicio de Reumatología, Hospital Reina Sofía, Córdoba; Benjamín Fernández-Gutiérrez and Luis Rodríguez-Rodríguez, Servicio de Reumatología, Hospital Clínico San Carlos, Madrid; Esther Vicente, Servicio de Reumatología, Hospital La Princesa, Madrid; José Luis Andreu, Servicio de Reumatología, Hospital Puerta del Hierro, Madrid; Paloma García de la Peña, Servicio de Reumatología, Hospital Madrid Norte Sanchinarro, Madrid; Francisco Javier López-Longo and Lina Martínez, Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid; Vicente Fonollosa, Servicio de Medicina Interna, Hospital Valle de Hebrón, Barcelona; Gerard Espinosa, Servicio de Medicina Interna, Hospital Clinic, Barcelona; Carlos Tolosa, Servicio de Medicina Interna, Hospital Parc Tauli, Sabadell; Anna Pros, Servicio de Reumatología, Hospital Del Mar, Barcelona; Mónica Rodríguez Carbalreira, Servicio de Medicina Interna, Hospital Universitari Mútua Terrasa, Barcelona; Francisco Javier Narváez, Servicio de Reumatología, Hospital Universitari de Bellvitge, Barcelona; Miguel Ángel González-Gay, Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander; Bernardino Díaz, Luis Trapiella and María Gallego, Servicio de Medicina Interna, Hospital Central de Asturias, Oviedo; María del Carmen Freire and Inés Vaqueiro, Unidad de Trombosis y Vasculitis, Servicio de Medicina Interna, Hospital Xeral-Complexo Hospitalario Universitario de Vigo, Vigo; María Victoria Egurbide, Servicio de Medicina Interna, Hospital de Cruces, Barakaldo; Luis Sáez-Comet, Unidad de Enfermedades Autoinmunes Sistémicas, Servicio de Medicina Interna, Hospital

Universitario Miguel Servet, Zaragoza; Federico Díaz and Vanesa Hernández, Servicio de Reumatología, Hospital Universitario de Canarias, Tenerife; Emma Beltrán and Servicio de Reumatología, Hospital del Doctor Peset Aleixandre, Valencia; José Andrés Román-Ivorra, Servicio de Reumatología, Hospital Universitari i Politècnic La Fe, Valencia.

REFERENCES

- Gabrielli, A., Avvedimento, E.V. and Krieg, T. (2009) Scleroderma. *N. Engl. J. Med.*, **360**, 1989–2003.
- Katsumoto, T.R., Whitfield, M.L. and Connolly, M.K. (2011) The pathogenesis of systemic sclerosis. *Annu. Rev. Pathol.*, **6**, 509–537.
- LeRoy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger, T.A. Jr, Rowell, N. and Wollheim, F. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. *J. Rheumatol.*, **15**, 202–205.
- Martin, J. and Fonseca, C. (2011) The genetics of scleroderma. *Curr. Rheumatol. Rep.*, **13**, 13–20.
- Radstake, T.R., Gorlova, O., Rueda, B., Martin, J.E., Alizadeh, B.Z., Palomino-Morales, R., Coenen, M.J., Vonk, M.C., Voskuyl, A.E., Schuerwegh, A.J. *et al.* (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. *Nat. Genet.*, **42**, 426–429.
- Zhernakova, A., van Diemen, C.C. and Wijmenga, C. (2009) Detecting shared pathogenesis from the shared genetics of immune-related diseases. *Nat. Rev. Genet.*, **10**, 43–55.
- Gregersen, P.K. and Olsson, L.M. (2009) Recent advances in the genetics of autoimmune disease. *Annu. Rev. Immunol.*, **27**, 363–391.
- Paunovic, V., Carroll, H.P., Vandenbroeck, K. and Gadina, M. (2008) Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. *Rheumatology (Oxford)*, **47**, 771–776.
- Caspi, R.R. (1998) IL-12 in autoimmunity. *Clin. Immunol. Immunopathol.*, **88**, 4–13.
- Hunter, C.A. (2005) New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. *Nat. Rev. Immunol.*, **5**, 521–531.
- Bacon, C.M., McVicar, D.W., Ortaldo, J.R., Rees, R.C., O’Shea, J.J. and Johnston, J.A. (1995) Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. *J. Exp. Med.*, **181**, 399–404.
- Jacobson, N.G., Szabo, S.J., Weber-Nordt, R.M., Zhong, Z., Schreiber, R.D., Darnell, J.E. Jr and Murphy, K.M. (1995) Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. *J. Exp. Med.*, **181**, 1755–1762.
- Ahn, H.J., Tomura, M., Yu, W.G., Iwasaki, M., Park, W.R., Hamaoka, T. and Fujiwara, H. (1998) Requirement for distinct Janus kinases and STAT proteins in T cell proliferation versus IFN-gamma production following IL-12 stimulation. *J. Immunol.*, **161**, 5893–5900.
- Airoldi, I., Di Carlo, E., Cocco, C., Sorrentino, C., Fais, F., Cilli, M., D’Antuono, T., Colombo, M.P. and Pistoia, V. (2005) Lack of IL12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. *Blood*, **106**, 3846–3853.
- Liu, Y., Helms, C., Liao, W., Zaba, L.C., Duan, S., Gardner, J., Wise, C., Miner, A., Malloy, M.J., Pullinger, C.R. *et al.* (2008) A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. *PLoS Genet.*, **4**, e1000041.
- Hirschfield, G.M., Liu, X., Xu, C., Lu, Y., Xie, G., Gu, X., Walker, E.J., Jing, K., Juran, B.D., Mason, A.L. *et al.* (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. *N. Engl. J. Med.*, **360**, 2544–2555.
- Remmers, E.F., Cosan, F., Kirino, Y., Ombrello, M.J., Abaci, N., Satorius, C., Le, J.M., Yang, B., Korman, B.D., Cakiris, A. *et al.* (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet’s disease. *Nat. Genet.*, **42**, 698–702.
- Mizuki, N., Meguro, A., Ota, M., Ohno, S., Shiota, T., Kawagoe, T., Ito, N., Kera, J., Okada, E., Yatsu, K. *et al.* (2010) Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. *Nat. Genet.*, **42**, 703–706.
- Rodriguez-Rodriguez, L., Carmona, F.D., Castaneda, S., Miranda-Filloy, J.A., Morado, I.C., Narvaez, J., Mari-Alfonso, B., Gomez-Vaquero, C., Amigo-Diaz, E., Rios-Fernandez, R. *et al.* (2011) Role of rs1343151 IL23R and rs3790567 IL12RB2 polymorphisms in biopsy-proven giant cell arteritis. *J. Rheumatol.*, **38**, 889–892.
- Nelis, M., Esko, T., Magi, R., Zimprich, F., Zimprich, A., Toncheva, D., Karachanak, S., Piskackova, T., Balasck, I., Peltonen, L. *et al.* (2009) Genetic structure of Europeans: a view from the North-East. *PLoS ONE*, **4**, e5472.
- Trinchieri, G., Pflanz, S. and Kastelein, R.A. (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. *Immunity*, **19**, 641–644.
- Duerr, R.H., Taylor, K.D., Brant, S.R., Rioux, J.D., Silverberg, M.S., Daly, M.J., Steinhardt, A.H., Abraham, C., Regueiro, M., Griffiths, A. *et al.* (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science*, **314**, 1461–1463.
- Oliver, J., Rueda, B., Lopez-Nevot, M.A., Gomez-Garcia, M. and Martin, J. (2007) Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. *Clin. Gastroenterol. Hepatol.*, **5**, 977–981.
- Cargill, M., Schrodi, S.J., Chang, M., Garcia, V.E., Brandon, R., Callis, K.P., Matsunami, N., Ardlie, K.G., Civeello, D., Catanese, J.J. *et al.* (2007) A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. *Am. J. Hum. Genet.*, **80**, 273–290.
- Burton, P.R., Clayton, D.G., Cardon, L.R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D.P., McCarthy, M.I., Ouwehand, W.H., Samani, N.J. *et al.* (2007) Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. *Nat. Genet.*, **39**, 1329–1337.
- Rueda, B., Orozco, G., Raya, E., Fernandez-Sueiro, J.L., Mulero, J., Blanco, F.J., Vilches, C., Gonzalez-Gay, M.A. and Martin, J. (2008) The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. *Ann. Rheum. Dis.*, **67**, 1451–1454.
- Nunez, C., Dema, B., Cenit, M.C., Polanco, I., Maluenda, C., Arroyo, R., de las Heras, V., Bartolome, M., de la Concha, E.G., Urcelay, E. *et al.* (2008) IL23R: a susceptibility locus for celiac disease and multiple sclerosis? *Genes Immun.*, **9**, 289–293.
- Jiang, Z., Yang, P., Hou, S., Du, L., Xie, L., Zhou, H. and Kijlstra, A. (2010) IL-23R gene confers susceptibility to Behcet’s disease in a Chinese Han population. *Ann. Rheum. Dis.*, **69**, 1325–1328.
- Rueda, B., Broen, J., Torres, O., Simeon, C., Ortego-Centeno, N., Schrijvenaars, M.M., Vonk, M.C., Fonollosa, V., van den Hoogen, F.H., Coenen, M.J. *et al.* (2009) The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype. *Ann. Rheum. Dis.*, **68**, 253–256.
- Agarwal, S.K., Gourh, P., Shete, S., Paz, G., Divecha, D., Reveille, J.D., Assassi, S., Tan, F.K., Mayes, M.D. and Arnett, F.C. (2009) Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. *J. Rheumatol.*, **36**, 2715–2723.
- Farago, B., Magyari, L., Safrany, E., Csonge, V., Jaromi, L., Horvatovich, K., Sipeky, C., Maasz, A., Radics, J., Gyetvai, A. *et al.* (2008) Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. *Ann. Rheum. Dis.*, **67**, 248–250.
- Sato, S., Hanakawa, H., Hasegawa, M., Nagaoka, T., Hamaguchi, Y., Nishijima, C., Komatsu, K., Hirata, A. and Takehara, K. (2000) Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. *J. Rheumatol.*, **27**, 2838–2842.
- Meloni, F., Caporali, R., Marone Bianco, A., Paschetto, E., Morosini, M., Fietta, A.M., Patrizio, V., Bobbio-Pallavicini, F., Pozzi, E. and Montecucco, C. (2004) BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. *Sarcoidosis Vasc. Diffuse Lung Dis.*, **21**, 111–118.
- Boin, F., De Fanis, U., Bartlett, S.J., Wigley, F.M., Rosen, A. and Casolaro, V. (2008) T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. *Arthritis Rheum.*, **58**, 1165–1174.
- Matsushita, T., Hasegawa, M., Hamaguchi, Y., Takehara, K. and Sato, S. (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. *J. Rheumatol.*, **33**, 275–284.

36. Banning, U., Krutmann, J. and Korholz, D. (2006) The role of IL-4 and IL-12 in the regulation of collagen synthesis by fibroblasts. *Immunol. Invest.*, **35**, 199–207.
37. Tsuji-Yamada, J., Nakazawa, M., Takahashi, K., Iijima, K., Hattori, S., Okuda, K., Minami, M., Ikezawa, Z. and Sasaki, T. (2001) Effect of IL-12 encoding plasmid administration on tight-skin mouse. *Biochem. Biophys. Res. Commun.*, **280**, 707–712.
38. Wu, C., Wang, X., Gadina, M., O’Shea, J.J., Presky, D.H. and Magram, J. (2000) IL-12 receptor beta 2 (IL-12R beta 2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites. *J. Immunol.*, **165**, 6221–6228.
39. Shevach, E.M., Chang, J.T. and Segal, B.M. (1999) The critical role of IL-12 and the IL-12R beta 2 subunit in the generation of pathogenic autoreactive Th1 cells. *Springer Semin. Immunopathol.*, **21**, 249–262.
40. Pistoia, V., Cocco, C. and Airoidi, I. (2009) Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. *J. Clin. Oncol.*, **27**, 4809–4816.
41. Allanore, Y., Saad, M., Dieude, P., Avouac, J., Distler, J.H., Amouyel, P., Matucci-Cerinic, M., Riemekasten, G., Airo, P., Melchers, I. *et al.* (2011) Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. *PLoS Genet.*, **7**, e1002091.
42. Gorlova, O., Martin, J.E., Rueda, B., Koeleman, B.P., Ying, J., Teruel, M., Diaz-Gallo, L.M., Broen, J.C., Vonk, M.C., Simeon, C.P. *et al.* (2011) Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. *PLoS Genet.*, **7**, e1002178.
43. Preliminary Criteria for the Classification of Systemic Sclerosis (Scleroderma). (1980) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum.*, **23**, 581–590.
44. LeRoy, E.C. and Medsger, T.A. Jr (2001) Criteria for the classification of early systemic sclerosis. *J. Rheumatol.*, **28**, 1573–1576.
45. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., Boehnke, M., Abecasis, G.R. and Willer, C.J. (2010) LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*, **26**, 2336–2337.
46. Skol, A.D., Scott, L.J., Abecasis, G.R. and Boehnke, M. (2006) Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat. Genet.*, **38**, 209–213.